Source: PipelineReview

OBT: Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody Platform for Five Bispecific Antibody Programs for up to $450 Million

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"),

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more